Rapt Therapeutics Q2 2024 Earnings Report

Rapt Therapeutics EPS Results

• Actual EPS: -$5.68
• Consensus EPS: -$5.92
• Beat/Miss: Beat by +$0.24
• One Year Ago EPS: N/A

Rapt Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Rapt Therapeutics Announcement Details

• Quarter: Q2 2024
• Date: 8/8/2024
• Time: Before Market Opens
• Conference Call Date: Thursday, August 8, 2024
• Conference Call Time: 7:00AM ET

Rapt Therapeutics (NASDAQ:RAPT), Inc (NASDAQ:RAPT) is a clinical-stage biotechnology company developing novel therapeutics for autoimmune and allergic diseases. Founded in 2013 and headquartered in San Diego, California, RAPT applies tissue-selective immunology to design small molecule and biologic candidates that modulate immune cell trafficking and tissue-resident pathways. The company’s research platform enables the identification of targets that drive tissue inflammation with the goal of achieving improved efficacy and safety profiles over current therapies.

The company’s lead asset, RPT193, is an orally available antagonist of the CC chemokine receptor 4 (CCR4), currently in clinical development for atopic dermatitis and allergic asthma. By selectively blocking CCR4-mediated migration of pathogenic T cells to inflamed tissues, RPT193 aims to reduce disease activity without broad immunosuppression. RAPT is also advancing discovery-stage programs against additional chemokine receptors involved in tissue inflammation, including efforts in ulcerative colitis and other indications.

Since its initial public offering in 2020, RAPT has expanded its operations across the United States, leveraging partnerships and collaborations to extend its global reach. The company maintains research and development facilities in San Diego and engages with clinical sites worldwide to advance its pipeline.

Under the leadership of Chief Executive Officer John C. Huggins, RAPT’s management team brings extensive experience in immunology, drug discovery and clinical development. The organization is guided by a board of directors and scientific advisors with deep expertise in translational research and biopharmaceutical innovation.